Project Grant R15DA063975
- This $507,000.00 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Icahn School of Medicine at Mount Sinai to investigate the epigenetic mechanisms underlying cannabis use disorder. The project, running from September 1, 2025 to May 31, 2030, aims to leverage a translational animal model of voluntary THC consumption to study sex differences and individual variability in...
- The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $686,692 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Medical University of South Carolina. The grant will fund an 8-week clinical trial to assess the prospective changes in patient-reported and objective functioning following reduction of cannabis use among adults with cannabis use disorder. The trial will evaluate the benefits of cannabis harm...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will provide $350,000 to Creighton University to investigate the effects of environmental enrichment on the abuse liability of minor cannabinoids such as delta-8-THC and CBD. The research aims to determine if adolescent exposure to high- or low-novelty environments can alter sensitivity to these cannabis compounds using animal models....
- This federal Project Grant award of $429,000.00 was provided by the National Institute on Drug Abuse (NIDA), which falls under the Drug Use and Addiction Research Programs (CFDA 93.279), to Oregon Health & Science University (OHSU). The objective of this project is to develop and apply new tools to precisely manipulate the effects of tetrahydrocannabinol (THC), the main psychoactive compound in marijuana, on the brain's reward circuitry. Specifically, the researchers have created...
- This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the impact of oral THC consumption during adolescence on the adult mouse brain. The $716,455 award, effective July 1, 2025 through March 31, 2030, will enable researchers at the University of Washington to: Determine how long-term adolescent use of THC-gelatin, alone or in combination with cannabidiol (CBD), impacts...
- The National Institute on Drug Abuse (NIDA) has awarded a $159,139 Project Grant to George Washington University (GWU) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant, awarded on August 15, 2025, will support research on the "Impact of Derived Psychoactive Cannabis Product Marketing on Perceptions and Use Among Young Adults." This project aims to investigate the effects of the marketing and availability of cannabis products on usage patterns and...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- This federal Project Grant award of $450,313 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the influence of psychotherapeutic advertising claims and mental health warning labels on online cannabis purchasing behaviors among individuals with symptoms of depression and/or anxiety. The project, titled "Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing," will...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This $616,372 federal Project Grant was awarded on July 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to identify neuronal, glial, and neural stem/progenitor cell transposable element (TE) transcriptional and epigenetic gene regulatory states involved in SIV, antiretroviral therapy, and cannabinoid exposure in a non-human primate model. Additionally, the research aims to identify TE expression...
This federal Project Grant award of $385,638 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the grant is to conduct research on the neurobehavioral consequences of chronic exposure to synthetic cannabinoids, also known as "synthetic marijuana", across different stages of lifespan development and between sexes. The research aims to elucidate the impact of chronic synthetic cannabinoid use on dopamine release and adaptive behavior, with the goal of raising public awareness of the dangers posed by this emerging class of drugs. The grant was awarded to the University of Colorado-Denver, a prominent public research university, and the project period runs from September 1, 2025 to August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $385.6k | 8/15/25 |